(FM) Oncología
Departamento académico
Luis
Montuenga Badía
Catedrático de Universidad
Publicacions en què col·labora amb Luis Montuenga Badía (23)
2024
2023
-
Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer
EMBO Reports, Vol. 24, Núm. 8
2022
-
Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis
Cancer Letters, Vol. 529, pp. 70-84
-
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity
The Journal of experimental medicine, Vol. 219, Núm. 12
-
YES1 Is a Druggable Oncogenic Target in SCLC
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403
2021
-
A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer
Translational Research, Vol. 233, pp. 77-91
-
Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma
Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337
2020
-
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade
Nature cancer, Vol. 1, Núm. 1, pp. 75-85
2018
-
A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients
Journal of Pathology, Vol. 245, Núm. 4, pp. 421-432
-
Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer
Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483
2017
-
Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer
Cancer Discovery, Vol. 7, Núm. 12, pp. 1420-1435
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
2016
-
Successful immunotherapy against a transplantable mouse squamous lung carcinoma with anti-PD-1 and anti-CD137 monoclonal antibodies
Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. 524-536
2015
2013
-
Identificación de marcadores genómicos con valor pronóstico en pacientes diagnosticados de carcinoma de pulmón en estadio temprano mediante microarrays de single nucleotide polymorphisms (SNPs)
Anales del sistema sanitario de Navarra, Vol. 36, Núm. 1, pp. 167-169
-
Investigation of complement activation product C4d as a diagnostic and prognostic biomarker for lung cancer
Journal of the National Cancer Institute, Vol. 105, Núm. 18, pp. 1385-1393
2011
-
Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance
Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4155-4166
2010
-
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
Molecular Cancer, Vol. 9
-
Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer
BMC Genomics, Vol. 11, Núm. 1
-
The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression
Clinical Cancer Research, Vol. 16, Núm. 16, pp. 4113-4125